Back to results
US H2,283 H1Granted
Vaccines for protecting against influenza
AssigneeNovartis AG
InventorsKlaus Stöhr, Philip Dormitzer, Giuseppe Del Giudice
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeNovartis AG
InventorsKlaus Stöhr, Philip Dormitzer, Giuseppe Del Giudice
Estimating the term…
A vaccine containing a H1 subtype influenza A virus hemagglutinin is either unadjuvanted or is adjuvanted but not with an oil-in-water emulsion adjuvant. The vaccine is suitable for immunizing a patient against swine flu. The vaccine may be monovalent. The vaccine may include two different H1 subtype influenza A virus hemagglutinins, wherein (i) the first H1 subtype influenza A virus hemagglutinin is more closely related to SEQ ID NO: 1 than to SEQ ID NO: 3 and (ii) the second H1 subtype influenza A virus hemagglutinin is more closely related to SEQ ID NO: 3 than to SEQ ID NO: 1. A monovalent vaccine may be administered in conjunction with a trivalent A/H1N1-A/H3N2 B seasonal influenza vaccine. Other embodiments are also disclosed, such as reassortant viruses.
A method for immunizing a subject, comprising administering two separate doses of unadjuvanted monovalent influenza vaccine to the subject, wherein (a) the two doses are administered from 1-6 weeks apart, and (b) each monovalent vaccine contains a H1 subtype influenza A virus hemagglutinin which is more closely related to SEQ ID NO:
A method for immunizing a subject, comprising administering two separate doses of unadjuvanted monovalent influenza vaccine to the subject, wherein (a) the two doses are administered from 1-6 weeks apart, and (b) each monovalent vaccine contains a H1 subtype influenza A virus hemagglutinin which has at least 85% sequence identity to SEQ ID NO:
A method for immunizing a subject, comprising administering to them by an intradermal route an unadjuvanted immunogenic composition comprising a H1 subtype influenza A virus hemagglutinin which is more closely related to SEQ ID NO:
A method for immunizing a subject, comprising administering to them by an intradermal route an unadjuvanted immunogenic composition comprising a H1 subtype influenza A virus hemagglutinin which has at least 85% sequence identity to SEQ ID NO:
Dependencies are inferred from the claim text.